文献速递心外重症与机械循环支持先天性心脏病外科

HeartMate 3 连续流心室辅助装置在儿童及先天性心脏病患者中的早期经验:多中心注册分析

Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis.
PubMed 文献 · J Heart Lung Transplant · 2020-02-13

中位随访 78 天,装置在体死亡 1 例(生存率 97%),20 例(57%)接受移植且无移植后死亡,无卒中或泵血栓事件。结论认为该装置在 ACTION 中心使用与低死亡率及不良事件发生率相关,最小成功植入体重 19 kg(BSA 0.78 m²),可能适用于较大儿童及小体重成人。

要点

  • HeartMate 3 在儿童及先心患者中早期生存率 97%,无卒中或泵血栓。
  • 最小成功植入体重 19 kg(BSA 0.78 m²),拓展了适用人群。
  • 57% 患者桥接至移植,移植后无死亡。

核心结论

  • HeartMate 3 在 ACTION 中心用于儿童及复杂先心患者与低死亡率及不良事件发生率相关。

主要发现

  • 中位年龄 15.7(8.8-47.3)岁,中位体重 65.7(19.1-114.1)kg,中位 BSA 1.74(0.78-2.36)m²。
  • 14 例(40%)体重 <60 kg;诊断包括扩张型心肌病(63%)、神经肌肉病相关扩张型心肌病(20%)及先天性心脏病(17%),先心中多数为 Fontan 循环。
  • 中位随访 78 天,装置在体死亡 1 例(生存率 97%);20/35(57%)接受移植,无移植后死亡;无卒中或泵血栓事件。

临床怎么用

  • 对于较大儿童及小体重成人(最小 19 kg,BSA 0.78 m²),HeartMate 3 可作为桥接移植的可行选择。

局限性

  • 样本量小(35 例),随访时间短(中位 78 天),为多中心注册回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The HeartMate 3 ventricular assist device (VAD) is a newer centrifugal continuous-flow VAD used for bridge-to-transplant and destination therapy in adults. However, there is limited experience regarding its use in children and adults with complex congenital heart disease (CHD). METHODS: The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) is a multicenter learning network comprised of pediatric hospitals implanting VADs in children and adults with complex CHD. We examined the outcomes of patients undergoing HeartMate 3 implantation at an ACTION center between December 2017 and September 2019. RESULTS: The HeartMate 3 was implanted in 35 patients at 9 ACTION centers, with a median age of 15.7 (8.8-47.3) years, median weight of 65.7 (19.1-114.1) kg, and median body surface area (BSA) of 1.74 (0.78-2.36) m2. Of the cohort, 14 patients (40%) weighed <60 kg. Diagnoses included dilated cardiomyopathy (63%), dilated cardiomyopathy in neuromuscular disease (20%), and CHD (17%). Of those with CHD, most had a Fontan circulation. With a median 78 days of follow-up, there was 1 death on device (97% survival); 20 out of 35 (57%) underwent transplantation with no post-transplantation mortality. There were no episodes of stroke or pump thrombosis. CONCLUSIONS: Use of the HeartMate 3 in ACTION centers was associated with a low incidence of mortality and adverse events. Patients as small as 19 kg (BSA 0.78 m2) were successfully implanted and supported, indicating that this device may be appropriate for older children and small adults.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. O'Connor MJ, Lorts A, Davies RR, et al. Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: A multicenter registry analysis. J Heart Lung Transplant. 2020. PMID: 32111350. doi:10.1016/j.healun.2020.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。